Epigenomics AG Successfully Validates Lung Cancer Test in Clinical Trial

24-Jun-2010 - Germany

Epigenomics AG successfully completed the pivotal performance evaluation study for its Epi proLung BL Reflex Assay, a lung cancer diagnostic test. The test determines the DNA methylation status of the SHOX2 gene in bronchial lavage material routinely obtained during the clinical workup of patients with suspected lung cancer. Increased DNA methylation of the SHOX2 gene indicates the presence of malignant lung disease. The study has demonstrated that the analytical and clinical performance fulfills the requirements for its intended use as an aid in the diagnosis of lung cancer. This successful performance evaluation meets an important clinical trial milestone as a regulatory prerequisite to CE-marking of in vitro diagnostic products prior to market introduction. The completion of the study now paves the way for the European launch of the Epi proLung BL Reflex Assay which is expected within the next few weeks.

In clinical care today, lung cancer is typically confirmed by the analysis of tissue that is directly obtained from the tumor or by analyzing cellular material e.g. from rinsing the airways with saline solution during a bronchial lavage. However, in approximately half of the suspected cancer cases neither cytology nor histology provide conclusive results at the time of a patient's first bronchoscopy. This frequently leads to further time consuming and costly procedures bearing additional risks for patients. The Epi proLung BL Reflex Assay test addresses this clear medical need by helping pathologists to confirm the presence of malignant lung disease.

"The Epi proLung BL Reflex Assay may provide critical additional information to pathologists when cytology is not unequivocal. This represents the diagnostic value of the test", stated Prof. Manfred Dietel, Director of the Institute of Pathology of Charité - University Medicine Berlin at a recent Key Opinion Leader Meeting in Frankfurt am Main, Germany, at which Epigenomics has introduced the novel test to pathologists and oncologists.

The clinical performance of the test has been demonstrated in a case control study with individuals that have undergone diagnostic work-ups for suspected lung cancer within the University of Liverpool Cancer Research Centre, Roy Castle Lung Cancer Research Program UK, under Professor John K Field. Using the Epi proLung BL Reflex Assay, the DNA methylation status of the SHOX2 gene was determined in routinely obtained bronchial lavage of patients with confirmed bronchial carcinoma and patients with no evidence of malignant lung disease but other lung diseases at the time of bronchoscopy and a minimum lung cancer free survival of 18 months. In this critical patient group, the test correctly identified 81% of the lung cancer cases with only 5% false positive results translating into a specificity of 95%. This clinical performance evaluation study confirms previous research studies showing that methylated SHOX2 DNA is a highly specific biomarker for lung cancer in bronchial lavage. Furthermore, the performance evaluation study has demonstrated that the Epi proLung BL Reflex Assay is a technically robust and reliable diagnostic tool. Simple handling, short time to results and compatibility with standard molecular diagnostic laboratory equipment are expected to facilitate introduction of this test into clinical routine.

Other news from the department research and development

These products might interest you

Mars 6

Mars 6 by CEM

Everything under Control - with This Intelligent Microwave Digestion System

High Sample Throughput with Just One Click

microwave digestion systems
SMART 6

SMART 6 by CEM

Moisture/Solids/Volatiles Analyzer: One System, Limitless Testing

moisture meters
tritec® Chromatographic refrigerators

tritec® Chromatographic refrigerators by tritec für Labortechnik und Umweltsimulation

Energy-efficient chromatography refrigerators for precise temperature control

Safe storage of your HPLC systems at -5 °C to 20 °C with modern touchscreen display

chromatography refrigerators
CrystalBreeder

CrystalBreeder by Technobis

CrystalBreeder: the next generation multi-reactor crystallization platform

Enhance your early stage solid state screening. New: controlled evaporation & vapor diffusion modes

Crystal16

Crystal16 by Technobis

Crystal16 - the ultimate instrument for research and process development

Upgrade your crystallization screens with the next generation benchtop crystallization system

crystallizers
OHAUS Laboratory equipment

OHAUS Laboratory equipment by Ohaus

Do More with OHAUS Laboratory Equipment

Do Not Limit Yourself to Just Measurement! Discover Ingenious Portfolio

lab equipment
FlowSyn and FlowSyn Maxi

FlowSyn and FlowSyn Maxi by Uniqsis

Continuous Flow Chemistry Systems for reaction optimisation and scale up

Perform reactions up to 300°C and 100 bar from 0.1 - 100 ml /minute

flow reactors
Loading...

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy